Pazopanib-Induced Asymptomatic Necrotizing Pancreatitis Diagnosed on 18F-FDG PET-CT Scan
暂无分享,去创建一个
[1] A. Agrawal,et al. Regorafenib-Associated Acute Pancreatitis Diagnosed on 18F-FDG PET/CT. , 2020, Clinical nuclear medicine.
[2] R. Desikan,et al. Delayed acute pancreatitis induced by nilotinib in a patient with chronic myeloid leukemia attaining sustained complete molecular response , 2020, EJHaem.
[3] C. Rolfo,et al. Pazopanib-induced asymptomatic radiological acute pancreatitis: A case report , 2017, Molecular and clinical oncology.
[4] G. Murtaza,et al. Acute Pancreatitis Related to a Chemotherapy Drug , 2017, World journal of oncology.
[5] Robin L. Jones,et al. Advanced soft-tissue sarcoma and treatment options: critical appraisal of trabectedin , 2016, Cancer management and research.
[6] B. Vincenzi,et al. Pazopanib and pancreatic toxicity: a case report , 2015, BMC Research Notes.
[7] G. Naik,et al. Pancreatitis with vascular endothelial growth factor receptor tyrosine kinase inhibitors. , 2014, Critical reviews in oncology/hematology.
[8] J. Reeves,et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. , 2013, The New England journal of medicine.
[9] J. Blay,et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial , 2012, The Lancet.
[10] J. Mayerle,et al. Drug-Induced Pancreatitis , 2012, Current Gastroenterology Reports.
[11] Patrick Schöffski,et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.